Picton Mahoney Asset Management Acquires 31,753 Shares of AbbVie Inc. $ABBV

Picton Mahoney Asset Management boosted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 41.3% during the third quarter, HoldingsChannel reports. The fund owned 108,567 shares of the company’s stock after purchasing an additional 31,753 shares during the quarter. Picton Mahoney Asset Management’s holdings in AbbVie were worth $25,138,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of ABBV. Hutchinson Capital Management CA acquired a new stake in shares of AbbVie in the 3rd quarter worth about $212,000. Victory Capital Management Inc. raised its stake in shares of AbbVie by 8.6% in the third quarter. Victory Capital Management Inc. now owns 1,525,632 shares of the company’s stock worth $350,656,000 after purchasing an additional 120,490 shares during the last quarter. Mathes Company Inc. bought a new position in shares of AbbVie in the third quarter valued at approximately $232,000. Accuvest Global Advisors boosted its position in shares of AbbVie by 1.3% during the third quarter. Accuvest Global Advisors now owns 4,151 shares of the company’s stock valued at $961,000 after buying an additional 52 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC grew its holdings in AbbVie by 2.8% during the third quarter. Focus Partners Advisor Solutions LLC now owns 36,230 shares of the company’s stock worth $8,203,000 after buying an additional 996 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive topline Phase 3 AFFIRM results for risankizumab (SKYRIZI) subcutaneous induction in moderately to severely active Crohn’s disease, showing superiority vs. placebo and no new safety signals — a material clinical win that expands AbbVie’s immunology franchise and supports future uptake. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn’s Disease
• Positive Sentiment: FDA approval for an oral combination of VENCLEXTA and acalabrutinib in previously untreated CLL adds an approved hematology-oncology option to AbbVie’s portfolio, supporting long-term revenue diversification in oncology. AbbVie’s New Data And Approval Test Growth And Valuation Story
• Positive Sentiment: Planned $380M investment to build two new active pharmaceutical ingredient manufacturing facilities in Illinois signals capacity expansion, vertical integration and potential margin/production benefits over time. Is AbbVie Inc. (ABBV) One of the Best Cancer Stocks to Invest In Now?
• Positive Sentiment: Multiple analyst/outlet pieces highlight AbbVie’s attractive dividend yield and steady payout growth, which can support investor demand from income-oriented funds and long-term investors. Why AbbVie Stock May Be the Ultimate Option for Dividend Investors
• Neutral Sentiment: Management will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 10), providing another opportunity for guidance clarity and incremental investor Q&A but not an immediate catalyst. AbbVie to Present at the Leerink Partners Global Healthcare Conference
• Neutral Sentiment: Mentions in industry reports on continuous manufacturing and market trends underscore structural tailwinds for pharma manufacturing efficiency but are longer‑term and indirect for AbbVie’s near-term stock moves. Continuous Manufacturing Market Trends and Global Forecasts, 2035 Featuring Key Players – AbbVie…
• Negative Sentiment: Despite the positive headlines, the stock is down today — likely reflecting short‑term profit-taking and a stretched valuation/PE that makes the name sensitive to market rotation and earnings expectations in the near term.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.08% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $233.44 on Wednesday. The firm has a market cap of $412.76 billion, a price-to-earnings ratio of 98.92, a P/E/G ratio of 0.81 and a beta of 0.34. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm’s 50-day simple moving average is $224.56 and its two-hundred day simple moving average is $223.66.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the previous year, the firm posted $2.16 EPS. AbbVie’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is presently 293.22%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Citigroup reduced their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Morgan Stanley increased their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. BMO Capital Markets restated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.